Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
InMed Pharmaceuticals Inc. (INM) had Return on Tangible Equity of -25.20% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.82M |
|
$-2.03M |
|
$0.64M |
|
$0.18M |
|
$2.94M |
|
$-2.12M |
|
$0.09M |
|
$-2.03M |
|
$-2.03M |
|
$-2.03M |
|
$-2.03M |
|
$-2.03M |
|
$-2.03M |
|
$-2.12M |
|
$-2.07M |
|
3.96M |
|
3.96M |
|
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$8.79M |
|
$0.76M |
|
$2.40M |
|
$11.19M |
|
$1.48M |
|
$0.12M |
|
$0.12M |
|
$1.60M |
|
$9.59M |
|
$8.05M |
|
$9.59M |
|
2.80M |
|
| Cash Flow Statement Financials | |
$-3.98M |
|
$0.00M |
|
$-0.14M |
|
$11.08M |
|
$6.95M |
|
$-4.12M |
|
$0.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.94 |
|
-- |
|
-- |
|
0.01 |
|
0.06 |
|
22.46% |
|
-258.57% |
|
-258.57% |
|
-- |
|
-247.29% |
|
-247.29% |
|
$-3.98M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.67 |
|
4.48 |
|
20.08 |
|
-21.15% |
|
|
Return on Tangible Equity |
-25.20% |
-18.12% |
|
-20.88% |
|
$3.42 |
|
$-1.01 |
|
$-1.01 |
|